Company / Cash & Equivalents
Innoviva, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$550.9M
FY2025
5-year range
$193.5M / $550.9M
FY2021-FY2025
Trend
+80.7%
vs FY2024
Sector context
#38 of 207
Health Care
What the data says
Innoviva, Inc.'s cash & equivalents of $551M is higher than 82% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 10 years, ranging from $62M in FY2018 to $551M in FY2025.
Based on SEC 10-K filings.
$551M in FY2025 with a 5-year CAGR of +17.5%. Top quartile in the Health Care sector.
Improved from $194M to $551M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +23.7%
- 5-Year CAGR
- +17.5%
- 10-Year CAGR
- -
Sector benchmark
-17.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +17.5%, indicating consistent growth.
- In FY2025, cash & equivalents increased 80.7% year-over-year.
- Ranks #38 out of 207 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2018.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $550.9M | +80.7% |
| FY2024 | $305.0M | +57.6% |
| FY2023 | $193.5M | -33.5% |
| FY2022 | $291.0M | +44.4% |
| FY2021 | $201.5M | -18.2% |
| FY2020 | $246.5M | -11.4% |
| FY2019 | $278.1M | +345.5% |
| FY2018 | $62.4M | -14.9% |
| FY2017 | $73.3M | -37.9% |
| FY2016 | $118.0M | -25.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026